Augustine Therapeutics
Augustine Therapeutics is a Belgian biotech developing treatments for neuromuscular and neurodegenerative diseases, having raised EUR 77.7M in a Series A round in the first half of 2025 with PMV participation.
Augustine Therapeutics focuses on therapeutic approaches to diseases affecting the nervous system and muscles, a field with significant unmet medical need and growing scientific understanding of underlying mechanisms. The company was co-founded by Ludo Van Den Bosch, Bart De Strooper, and Joris De Wit, researchers with strong academic credentials in neuroscience.
The EUR 77.7M Series A, raised in H1 2025, is one of the larger biotech rounds in recent Belgian history and provides substantial capital for clinical development. PMV, the Flemish public investment vehicle, is among the backers, reflecting the strategic interest in building a durable life sciences sector in Flanders.
Funding History
- Series A: EUR 77.7M (H1 2025)
